Search - tctmd.com

Displaying 21 - 40 of 43

Sort: Relevancy | Date

Presentation CADECI 2015

Uso responsable de rivaroxabán en prevención secundaria tras un SICA

Presenter: Dr. Carlos Felipe Barrera-Ram?rez

February 19, 2015

Presentation TCT 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson

September 15, 2014

Presentation

Efficacy, Safety of Rivaroxaban vs Warfarin in Elderly Patients with Nonvalvular A-fib

Presenter: Jonathan L. Halperin

June 09, 2014

Presentation

Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial

Presenter: Ka Sing Lawrence Wong

April 29, 2014

Presentation

Intracranial Hemorrhage Among Patients with A-Fib Anticoagulated with Warfarin or Rivaroxaban

Presenter: Graeme J. Hankey

April 22, 2014

Presentation

A Phase 2 Placebo-Controlled Trial Demonstrating Reversal of Rivaroxaban-induced Anticoagulation

Presenter: Mark Crowther

December 22, 2013

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

Presentation TCT 2013

Case Presentation: A Patient With Atrial Fibrillation on Rivaroxaban Who Develops a STEMI

Presenter: E. Magnus Ohman

October 31, 2013

Presentation

Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-fibfib

Presenter: Sean van Diepen

June 10, 2013

Presentation

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Presenter: C. Michael Gibson

April 17, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Presentation

Rivaroxaban in Patients Stabilized After STEMI: Results from the ATLAS ACS 2-TIMI 51 Trial

Presenter: Jessica L. Mega

March 04, 2013

Presentation

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular A-fib

Presenter: Manesh R. Patel

February 03, 2013

Presentation AHA 2012

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Presenter: Saurav Chatterjee

November 04, 2012

Presentation TCT 2012

Should Rivaroxaban Be Used in STEMI Patients, and Does Choice of ADP Antagonist (with Rivaroxaban) Matter?

Presenter: C. Michael Gibson

October 25, 2012

Presentation TCT 2012

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

Presenter: C. Michael Gibson

October 24, 2012

Presentation TCT 2012

ATLAS ACS-2 TIMI 51: Stent thrombosis in Patients with Acute Coronary Syndromes treated with Rivaroxaban

Presenter: C. Michael Gibson

October 24, 2012

Presentation TCT 2012

Late Breaking Clinical Trials: Venous Thromboembolic Disease EINSTEIN-PE (Rivaroxaban)

Presenter: Jeffrey Kuvin

October 23, 2012

Presentation TCT 2012

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Presenter: Harvey White

October 22, 2012

Presentation ESC 2012

Rivaroxaban in Patients following a ST-Elevation Myocardial Infarction

Presenter: Jessica L. Mega

August 27, 2012

Advertisement

Uso responsable de rivaroxabán en prevención secundaria tras un SICA

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Efficacy, Safety of Rivaroxaban vs Warfarin in Elderly Patients with Nonvalvular A-fib

Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial

Intracranial Hemorrhage Among Patients with A-Fib Anticoagulated with Warfarin or Rivaroxaban

A Phase 2 Placebo-Controlled Trial Demonstrating Reversal of Rivaroxaban-induced Anticoagulation

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Case Presentation: A Patient With Atrial Fibrillation on Rivaroxaban Who Develops a STEMI

Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-fibfib

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Rivaroxaban in Patients Stabilized After STEMI: Results from the ATLAS ACS 2-TIMI 51 Trial

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular A-fib

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Should Rivaroxaban Be Used in STEMI Patients, and Does Choice of ADP Antagonist (with Rivaroxaban) Matter?

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

ATLAS ACS-2 TIMI 51: Stent thrombosis in Patients with Acute Coronary Syndromes treated with Rivaroxaban

Late Breaking Clinical Trials: Venous Thromboembolic Disease EINSTEIN-PE (Rivaroxaban)

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Rivaroxaban in Patients following a ST-Elevation Myocardial Infarction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content